ReviewFrontiers in immunology2026
Macrophage polarization in ischemia-reperfusion injury: from molecular mechanisms to therapeutic strategies.
Review in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ischemia-reperfusion injury (IRI) induces secondary tissue damage following the restoration of blood flow. Currently, there is a lack of specific therapeutic interventions for IRI. Macrophage M1/M2 polarization plays a pivotal role in the progression of IRI; however, integrated analyses of its dynamic changes and organ-specific characteristics remain insufficient. This review focuses on the critical role of macrophage M1/M2 phenotypic balance in IRI, systematically elucidating the mechanisms underlying its dynamic regulation. It highlights, for the first time, the impact of metabolic reprogramming and mechanical signaling on polarization imbalance and provides a comprehensive analysis of the organ-specific features of macrophages in four common target organs of reperfusion injury (heart, brain, liver, and kidney). In terms of interventional strategies, cutting-edge approaches are emphasized, including epigenetic drugs, nanoparticle-based targeted delivery systems, and temporally sequenced combination therapies, to achieve precise temporal regulation from suppression of M1-mediated inflammation to promotion of M2-driven repair. In the future, integration of multi-omics and spatiotemporal dynamic analyses will be essential to construct organ-specific and stage-adaptive immune intervention frameworks, thereby advancing the treatment of IRI toward personalization and precision medicine.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.